ATRIVA (IDFF)

Projektträger – zwischengeschaltetes Finanzinstitut

ATRIVA THERAPEUTICS GMBH

Ort

• Deutschland

Beschreibung

Financing the borrower's research and development (R&D) and clinical trials related to its novel antiviral drug ATR-002, which will target influenza and other respiratory viruses, including SARS-CoV-2.

Ziele

The project supports a biotech company to develop a novel antiviral medicinal product for influenza and other respiratory viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The eligible investment plan includes R&D and related expenses.

Sektor(en)

• Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen

Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)

EUR 24 million

Gesamtkosten (voraussichtlicher Betrag)

EUR 30 million

Umweltaspekte

The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

Auftragsvergabe

The Promoter is a private company not operating in the utilities sector and not having the status of a contracting authority; thus, the project is not covered by the EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

Projektstatus

Unterzeichnet - 16/10/2020